MovDisordV3, Main, Exploration, bibRecord, 004759

Long‐term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease

Identifieur interne : 004759 ( Main/Exploration ); précédent : 004758; suivant : 004760

Long‐term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease

Auteurs : Jean-Louis Montastruc [France] ; Karine Desboeuf [France] ; Maryse Lapeyre-Mestre [France] ; Jean-Michel Senard [France] ; Olivier Rascol [France] ; Christine Brefel-Courbon [France]

Source :

Movement Disorders [ 0885-3185 ] ; 2001-05.

RBID : ISTEX:DB129378E12554A8F9378511E8F16E3C6FB4CCFD

Descripteurs français

Pascal (Inist)
- Antiparkinsonien, Bromocriptine, Chimiothérapie, Ergot dérivé, Homme, Long terme, Lévodopa, Mortalité, Parkinson maladie, Traitement.
Wicri :
- geographic : France.
- topic : Homme, Mortalité.

English descriptors

KwdEn :
- Aged, Antiparkinson Agents (administration & dosage), Antiparkinson Agents (therapeutic use), Antiparkinson agent, Bromocriptine, Bromocriptine (administration & dosage), Bromocriptine (therapeutic use), Chemotherapy, Drug Therapy, Combination, Ergot derivatives, Female, Follow-Up Studies, France (epidemiology), Human, Humans, Levodopa, Levodopa (administration & dosage), Levodopa (therapeutic use), Long term, Male, Middle Aged, Mortality, Mortality (trends), Parkinson Disease (drug therapy), Parkinson Disease (mortality), Parkinson disease, Parkinson's disease, Prospective Studies, Treatment, Treatment Outcome, bromocriptine, levodopa, mortality.
MESH :
- chemical , administration & dosage : Antiparkinson Agents, Bromocriptine, Levodopa.
- chemical , therapeutic use : Antiparkinson Agents, Bromocriptine, Levodopa.
- geographic , epidemiology : France.
- drug therapy : Parkinson Disease.
- mortality : Parkinson Disease.
- trends : Mortality.
- Aged, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prospective Studies, Treatment Outcome.

Abstract

The present paper compares, in terms of mortality, two treatment regimens for Parkinson's disease (PD), i.e., bromocriptine later combined with levodopa versus levodopa only. Between 1982 and 1989, 60 PD patients (29 treated with levodopa alone [group D] and 31 receiving first bromocriptine followed by an association of bromocriptine + levodopa [group B/D]) were recruited. Data were updated in January 2000. Survival functions were estimated using Kaplan Meier product‐limit method and comparison between the two groups with the log‐rank test. Mortality was also compared with that of the general French population using standardized mortality ratios (SMRs). The mean duration of follow‐up was 10.3 ± 3.0 years. Seventeen patients died during the follow‐up: nine in the group B/D and eight in the group D. The probability of survival at 10 years was 79.0% [95% confidence interval [CI]: 71.4–86.6] in group B/D and 72.9% [95% CI: 63.3–82.6] in group D. In comparison with the general French population, SMRs were not statistically different from 1, in the whole sample of PD patients (1.21, 95 % CI [0.71–1.95]), in group D (0.98 [0.42–1.93]), or in group B/D (1.53 [0.70–2.92]). In this population, we were unable to find any favourable effect of an early use of bromocriptine on mortality in PD in comparison with levodopa alone. © 2001 Movement Disorder Society.

Url:

https://api.istex.fr/document/DB129378E12554A8F9378511E8F16E3C6FB4CCFD/fulltext/pdf

DOI: 10.1002/mds.1093

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long‐term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease</title>
<author><name sortKey="Montastruc, Jean Ouis" sort="Montastruc, Jean Ouis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name>
</author>
<author><name sortKey="Desboeuf, Karine" sort="Desboeuf, Karine" uniqKey="Desboeuf K" first="Karine" last="Desboeuf">Karine Desboeuf</name>
</author>
<author><name sortKey="Lapeyre Estre, Maryse" sort="Lapeyre Estre, Maryse" uniqKey="Lapeyre Estre M" first="Maryse" last="Lapeyre-Mestre">Maryse Lapeyre-Mestre</name>
</author>
<author><name sortKey="Senard, Jean Ichel" sort="Senard, Jean Ichel" uniqKey="Senard J" first="Jean-Michel" last="Senard">Jean-Michel Senard</name>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation><country>France</country>
<placeName><settlement type="city">Toulouse</settlement>
<region type="region" nuts="2">Midi-Pyrénées</region>
</placeName>
<orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName>
<orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName>
</affiliation>
</author>
<author><name sortKey="Brefel Ourbon, Christine" sort="Brefel Ourbon, Christine" uniqKey="Brefel Ourbon C" first="Christine" last="Brefel-Courbon">Christine Brefel-Courbon</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:DB129378E12554A8F9378511E8F16E3C6FB4CCFD</idno>
<date when="2001" year="2001">2001</date>
<idno type="doi">10.1002/mds.1093</idno>
<idno type="url">https://api.istex.fr/document/DB129378E12554A8F9378511E8F16E3C6FB4CCFD/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002A97</idno>
<idno type="wicri:Area/Istex/Curation">002A97</idno>
<idno type="wicri:Area/Istex/Checkpoint">002F86</idno>
<idno type="wicri:doubleKey">0885-3185:2001:Montastruc J:long:term:mortality</idno>
<idno type="wicri:Area/Main/Merge">006C41</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:01-0377069</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002A08</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000313</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002964</idno>
<idno type="wicri:doubleKey">0885-3185:2001:Montastruc J:long:term:mortality</idno>
<idno type="wicri:Area/Main/Merge">006E63</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:11391747</idno>
<idno type="wicri:Area/PubMed/Corpus">003D40</idno>
<idno type="wicri:Area/PubMed/Curation">003D40</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003D08</idno>
<idno type="wicri:Area/Ncbi/Merge">000511</idno>
<idno type="wicri:Area/Ncbi/Curation">000511</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000511</idno>
<idno type="wicri:doubleKey">0885-3185:2001:Montastruc J:long:term:mortality</idno>
<idno type="wicri:Area/Main/Merge">006A10</idno>
<idno type="wicri:Area/Main/Curation">004759</idno>
<idno type="wicri:Area/Main/Exploration">004759</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Long‐term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease</title>
<author><name sortKey="Montastruc, Jean Ouis" sort="Montastruc, Jean Ouis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse</wicri:regionArea>
<wicri:noRegion>Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion>
<wicri:noRegion>Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Desboeuf, Karine" sort="Desboeuf, Karine" uniqKey="Desboeuf K" first="Karine" last="Desboeuf">Karine Desboeuf</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse</wicri:regionArea>
<wicri:noRegion>Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion>
<wicri:noRegion>Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lapeyre Estre, Maryse" sort="Lapeyre Estre, Maryse" uniqKey="Lapeyre Estre M" first="Maryse" last="Lapeyre-Mestre">Maryse Lapeyre-Mestre</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse</wicri:regionArea>
<wicri:noRegion>Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion>
<wicri:noRegion>Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Senard, Jean Ichel" sort="Senard, Jean Ichel" uniqKey="Senard J" first="Jean-Michel" last="Senard">Jean-Michel Senard</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse</wicri:regionArea>
<wicri:noRegion>Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion>
<wicri:noRegion>Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse</wicri:regionArea>
<wicri:noRegion>Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion>
<wicri:noRegion>Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion>
<placeName><settlement type="city">Toulouse</settlement>
<region type="region" nuts="2">Midi-Pyrénées</region>
</placeName>
<orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName>
<orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName>
</affiliation>
</author>
<author><name sortKey="Brefel Ourbon, Christine" sort="Brefel Ourbon, Christine" uniqKey="Brefel Ourbon C" first="Christine" last="Brefel-Courbon">Christine Brefel-Courbon</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse</wicri:regionArea>
<wicri:noRegion>Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion>
<wicri:noRegion>Faculté de Médecine and Hôpitaux de Toulouse</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>John Wiley & Sons, Inc.</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="2001-05">2001-05</date>
<biblScope unit="vol">16</biblScope>
<biblScope unit="issue">3</biblScope>
<biblScope unit="page" from="511">511</biblScope>
<biblScope unit="page" to="514">514</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">DB129378E12554A8F9378511E8F16E3C6FB4CCFD</idno>
<idno type="DOI">10.1002/mds.1093</idno>
<idno type="ArticleID">MDS1093</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Antiparkinson Agents (administration & dosage)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Antiparkinson agent</term>
<term>Bromocriptine</term>
<term>Bromocriptine (administration & dosage)</term>
<term>Bromocriptine (therapeutic use)</term>
<term>Chemotherapy</term>
<term>Drug Therapy, Combination</term>
<term>Ergot derivatives</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>France (epidemiology)</term>
<term>Human</term>
<term>Humans</term>
<term>Levodopa</term>
<term>Levodopa (administration & dosage)</term>
<term>Levodopa (therapeutic use)</term>
<term>Long term</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Mortality</term>
<term>Mortality (trends)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (mortality)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Prospective Studies</term>
<term>Treatment</term>
<term>Treatment Outcome</term>
<term>bromocriptine</term>
<term>levodopa</term>
<term>mortality</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Bromocriptine</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Bromocriptine</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>France</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Mortality</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Prospective Studies</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Antiparkinsonien</term>
<term>Bromocriptine</term>
<term>Chimiothérapie</term>
<term>Ergot dérivé</term>
<term>Homme</term>
<term>Long terme</term>
<term>Lévodopa</term>
<term>Mortalité</term>
<term>Parkinson maladie</term>
<term>Traitement</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>France</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
<term>Mortalité</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The present paper compares, in terms of mortality, two treatment regimens for Parkinson's disease (PD), i.e., bromocriptine later combined with levodopa versus levodopa only. Between 1982 and 1989, 60 PD patients (29 treated with levodopa alone [group D] and 31 receiving first bromocriptine followed by an association of bromocriptine + levodopa [group B/D]) were recruited. Data were updated in January 2000. Survival functions were estimated using Kaplan Meier product‐limit method and comparison between the two groups with the log‐rank test. Mortality was also compared with that of the general French population using standardized mortality ratios (SMRs). The mean duration of follow‐up was 10.3 ± 3.0 years. Seventeen patients died during the follow‐up: nine in the group B/D and eight in the group D. The probability of survival at 10 years was 79.0% [95% confidence interval [CI]: 71.4–86.6] in group B/D and 72.9% [95% CI: 63.3–82.6] in group D. In comparison with the general French population, SMRs were not statistically different from 1, in the whole sample of PD patients (1.21, 95 % CI [0.71–1.95]), in group D (0.98 [0.42–1.93]), or in group B/D (1.53 [0.70–2.92]). In this population, we were unable to find any favourable effect of an early use of bromocriptine on mortality in PD in comparison with levodopa alone. © 2001 Movement Disorder Society.</div>
</front>
</TEI>
<affiliations><list><country><li>France</li>
</country>
<region><li>Midi-Pyrénées</li>
</region>
<settlement><li>Toulouse</li>
</settlement>
<orgName><li>Université Toulouse III - Paul Sabatier</li>
<li>Université de Toulouse</li>
</orgName>
</list>
<tree><country name="France"><noRegion><name sortKey="Montastruc, Jean Ouis" sort="Montastruc, Jean Ouis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name>
</noRegion>
<name sortKey="Brefel Ourbon, Christine" sort="Brefel Ourbon, Christine" uniqKey="Brefel Ourbon C" first="Christine" last="Brefel-Courbon">Christine Brefel-Courbon</name>
<name sortKey="Desboeuf, Karine" sort="Desboeuf, Karine" uniqKey="Desboeuf K" first="Karine" last="Desboeuf">Karine Desboeuf</name>
<name sortKey="Lapeyre Estre, Maryse" sort="Lapeyre Estre, Maryse" uniqKey="Lapeyre Estre M" first="Maryse" last="Lapeyre-Mestre">Maryse Lapeyre-Mestre</name>
<name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<name sortKey="Senard, Jean Ichel" sort="Senard, Jean Ichel" uniqKey="Senard J" first="Jean-Michel" last="Senard">Jean-Michel Senard</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004759 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004759 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:DB129378E12554A8F9378511E8F16E3C6FB4CCFD
   |texte=   Long‐term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Long‐term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease

Long‐term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.